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Summary
The Italian region of Lombardy, with its existing stroke
centers and high-technology laboratories,  provides a
favorable context for studying monogenic diseases as-
sociated with stroke. The Lombardia GENS project was
set up to create a regional network for the diagnosis of
six monogenic diseases associated with stroke:
CADASIL, Fabry disease, MELAS, familial and sporadic
hemiplegic migraine, hereditary cerebral amyloid an-
giopathy and Marfan syndrome. The network compris-
es 36 stroke centers and seven high-technology labora-
tories, performing molecular analysis. In this context,
all stroke/TIA patients fulﬁlling clinical criteria for
monogenic diseases are currently being included in an
ongoing study. Demographic, clinical and family data
and diagnostic criteria are collected using standardized
forms. On the basis of stroke incidence in Lombardy
and the reported prevalence of the diseases consid-
ered, we expect, during the course of the study, to col-
lect datasets and DNA samples from more than 200
stroke patients suspected of having monogenic dis-
eases. This will allow evaluation of the regional burden
and better phenotype characterization of monogenic
diseases associated with stroke.
KEY WORDS: cerebrovascular disease, genetics, monogenic disor-
ders, stroke
Introduction
Stroke is a leading cause of mortality and long-term dis-
ability. To relieve the heavy burden of stroke, there is a
need for better understanding of its pathogenetic mech-
anisms, in order to improve its prevention and treatment. 
The genetic contribution to stroke is well established
and there is evidence that genetic factors inﬂuence
stroke occurrence and outcome (1,2). Underlying mono-
genic diseases account for about 1% to 5% of all
strokes, although their incidence is believed to be under-
estimated. In fact, monogenic disorders can be misdiag-
nosed simply because physicians fail to include them in
the differential diagnosis. Moreover, even when there
are elements that may support a genetic cause, such as
young age at onset, positive family history, presence of
speciﬁc associated clinical features, and absence of
conventional vascular risk factors, the wide phenotypic
spectrum makes it difﬁcult to select patients and decide
which disorders to screen for. However, these disorders,
although rare, are usually life-threatening or chronically
debilitating diseases; because of their low prevalence
and high complexity they are also difﬁcult to manage.
The diagnosis of these disorders is important both for
genetic counseling and therapeutic decision-making (3-
5). In this context, the identiﬁcation of a large number of
patients affected by monogenic diseases may help to
better clarify stroke pathogenesis and lead to the devel-
opment of potential new drugs and therapeutic targets.
Also, careful selection of phenotypes is considered an
essential requirement for all genetic studies (6). 
In the Italian region of Lombardy (about 6 million inhab-
itants) there is a clinical network of neurological centers
specialized in stroke diagnosis and care, including 29
stroke units; the region also has seven high-technology
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laboratories with well-established expertise in stroke ge-
netics. The presence of these centers prompted the cre-
ation of a regional stroke genetics network (Lombardia
GENS) designed to exploit the databases of the existing
clinical stroke network and also beneﬁt from collabora-
tion with laboratories interested in stroke genetics. 
The Lombardia GENS project is a prospective multicen-
ter cohort study aimed at organizing a structured service
for complete diagnosis of six single-gene disorders as-
sociated with stroke [CADASIL, Fabry disease, MELAS,
familial and sporadic hemiplegic migraine (FHM/SHM),
hereditary cerebral amyloid angiopathy (H-CAA), and
Marfan syndrome] through the setting up of a speciﬁc di-
agnostic work-up for patients with clinically suspected
genetic diseases. The aim of the project is to create a
regional database and DNA biobank of well-phenotyped
stroke patients for studies on regional incidence of
monogenic diseases in stroke, phenotypic characteriza-
tion, and therapeutic trials.
Study design and population
The study population consists of a continuous series of
patients with stroke or transient ischemic attack (TIA), in
whom there is clinical suspicion of one of the following
monogenic diseases: CADASIL, Fabry disease,
MELAS, FHM/SHM, H-CAA, or Marfan syndrome, re-
ferred during the study period to the clinical units partic-
ipating in the project. Both ischemic and hemorrhagic
strokes are included. The coordinating center managing
the project is the Neurology Unit at the Ca’ Granda
Foundation, Maggiore Policlinico Hospital, IRCCS, Uni-
versity of Milan, Italy, which is supported by a scientiﬁc
steering committee (SC). The SC comprises members
from the Neurology Unit, Ca’ Granda Foundation, Mag-
giore Policlinico Hospital, IRCCS, University of Milan;
the Cerebrovascular Unit, Carlo Besta Institute of Neu-
rology Foundation, IRCCS, Milan; the Emergency Unit,
C. Mondino National Institute of Neurology Foundation,
IRCCS, Pavia; the Stroke Unit, Niguarda Ca’ Granda
Hospital, Milan; the Stroke Unit, Division of Neuro-
science & Institute of Experimental Neurology (INSPE),
San Raffaele Scientiﬁc Foundation, Milan, the CNS In-
ﬂammatory Unit, Division of Neuroscience & Institute of
Experimental Neurology (INSPE), San Raffaele Scientif-
ic Foundation, Milan, the Stroke Unit, San Gerardo Hos-
pital, University of Milan-Bicocca, Monza, and the De-
partment of Clinical and Experimental Sciences, Neurol-
ogy Clinic, University of Brescia, Italy.
Clinical centers that hospitalize more than 100 patients
for stroke annually are included. The project envisages
a two-step diagnostic pathway. Through a standardized
form, stroke physicians in the participating units collect
the demographic and clinical data of all stroke patients
with a suspected genetic cause (‘probable cases’). The
form includes demographic data, family antecedents,
racial descent, current pathologies, and stroke risk fac-
tors. Strokes are classiﬁed according to established
standardized criteria (hemorrhagic, ischemic, TOAST,
and Oxfordshire classiﬁcation). Findings from neu-
roimaging and instrumental examinations are also
recorded, as are other associated neurological or sys-
temic clinical features. It is also envisaged that physi-
cians ﬁll in clinical and radiological diagnostic algo-
rithms, developed from literature data and speciﬁc for
each monogenic disease in order to address the dis-
ease suspicion (‘suspected case’). 
The use of these standardized forms and a centralized
training procedure for all clinicians participating in the
patient data collection ensures standardized and homo-
geneous data collection across the participating centers.
Furthermore, the validity of the screening procedure is
periodically validated at meetings of representatives
from the centers and laboratories and the group of ex-
perts belonging to the scientiﬁc steering committee. All
data are stored in a computer database (Access format).
On receipt of forms from the centers and laboratories,
data are entered centrally by the staff at the coordinat-
ing center, who also apply quality evaluation processes.
Two advisors (Prof. Hugh Markus, Centre for Clinical
Neuroscience, St George’s University of London, and Dr
Caspar Grond Ginsbach, Neurologische Klinik Univer-
sität, Heidelberg) collaborated on the project design and
thus provided a further guarantee of the quality of the
project. Nine trained clinical monitors, who visit all the
participating clinical centers every two weeks, are work-
ing to guarantee the recruitment of a continuous series
of suspected cases, as well as the accuracy and com-
pleteness of the data. Periodic monitoring of the partici-
pating centers reduces the risk of missed cases.
Genetic analysis
Blood samples for DNA analysis are collected during
each patient’s hospital stay as well as during outpatient
activity, after obtaining patient informed consent accord-
ing to the local ethics regulations. All centers guarantee
correct acquisition of informed consent; this includes
providing patients with a full description of the project’s
goals as well as informing them of the possibility that bi-
ological material collected may be used for future analy-
ses still to be deﬁned at the time of the acquisition of
consent. The use and sharing of biospecimens and as-
sociated clinical data complies with all applicable priva-
cy and human subjects’ protection regulations. All sam-
ples are processed by automatic extraction to obtain
high purity DNA and stored locally at -80°C. Blood sam-
ples are sent together with the clinical and criteria forms
to the speciﬁc laboratories for the genetic diagnosis. The
genetic diagnosis is obtained by performing the follow-
ing evaluations:
• for CADASIL, screening of exons 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23
of the NOTCH3 gene on chromosome 19; 
• for Fabry disease, α-galactosidase activity initially in all
suspected men; in suspected women and in men with
reduced α-galactosidase activity, a genetic screening of
the seven most frequently mutated exons of the α-GAL
A (Xq 22.1) gene; 
• for MELAS, screening for point mutations in the
tRNALeu gene on mtDNA; in highly suspected cases or
in cases with a muscular biopsy consistent with mito-
chondrial myopathy, screening for other mtDNA muta-
tions, e.g. in the MTTL1 gene and other tRNA genes
(MTTF, MTTv, MTTQ) as well as in other subunits of
complex 1 such as MTND1, MTND5, and MTND6; 
• for FHM/SHM, screening of all exons of the ATP1A2
gene; exons 3, 4, 5, 6, 11, 13, 14, 16, 17, 19, 20, 22, 23,
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24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 41, 42, and
47 of the CACNA1A gene; and exons 23 and 26 of the
SCN1A gene;
• for H-CAA, sequencing in suspected cases of all exons
of TRANSTHYRETIN, CYSTATIN C, and AMYLOID
PRECURSOR PROTEIN gene; and 
• for Marfan syndrome, because the diagnosis is estab-
lished on clinical grounds (5), molecular analysis consist-
ing of whole-exon screening of the FB1 and TGFβ-R2
genes will be performed only in highly suspected cases. 
The project involves the use of clinical and personal da-
ta and of blood samples for DNA extraction. The source
of genetic material is venous blood collected from the
patients by standard blood-drawing methods. No per-
sonal risks are envisaged for the patients involved since
they are not exposed to any treatment or challenge. Ital-
ian national rules on data protection are complied with,
and patient anonymity is guaranteed. The results of ge-
netic tests are communicated to physicians in charge of
the cases, who are responsible for informing the patient,
or next of kin, of diagnostic test results and of the result-
ing diagnosis, according to local ethics regulations. 
For data analysis, a database encryption strategy has
been developed. Since results from single individuals
would not be informative, information is extracted from
group data. Thus, all published data will be at group, not
individual, level.
Statistical analysis
Before the planned results analysis, a quality evaluation
will be performed and the validity of the screening pro-
cedures assessed. The analysis will be carried out cen-
trally, by the coordinating center, using the full dataset.
Correlation analysis of phenotype and genotype charac-
teristics will be performed on the total population as well
as on different subgroups. A subgroup analysis of stroke
subtypes is also planned. An analysis of monogenic dis-
ease incidence in the regional stroke population, strati-
ﬁed by sex and age, will also be performed.
Expected results
Through the present study, which involves the creation
of an integrated regional network of clinical centers and
laboratories and the coordination of their activity, and its
results, we expect to provide a good practical example
for the implementation of similar projects and for the di-
agnosis of other monogenic disorders. In addition, our
network is expected to be a useful tool for supporting re-
search excellence in stroke genetics. A cohort of well-
phenotyped and well-characterized stroke patients, ho-
mogeneously collected, is expected to provide good-
quality results in terms of: i) better knowledge of the nat-
ural history of monogenic disorders; ii) more accurate
deﬁnitions of phenotypes associated with monogenic
disorders; iii) identiﬁcation of possible genotype-pheno-
type correlations; iv) identiﬁcation of additional environ-
mental and risk factors modulating the disease process
or variably contributing to the full disease phenotype;
and v) the creation of a proven network for future collab-
oration in therapeutic clinical trials targeting prevention
of disease progression or symptom relief.
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Figure 1 - Lombardia GENS recruiting centers 
Preliminary results
Thirty-three clinical units among the region’s centers
hospitalizing more than 100 stroke patients each year
are participating in the project (Fig. 1). These centers
cumulatively hospitalize about 10,000 stroke patients
annually, representing about 90% of all stroke cases in
Lombardy. Although the recruiting period was intended
to start in January 2008, patient data collection began
later than the anticipated date because most centers
were waiting for local ethics committee approval. More-
over, clinicians required a start-up period, which meant
that the initial recruitment phase moved slowly. After
April, 2008 recruitment became steady and improved
further following the introduction of clinical monitors in
December 2008. 
In about three years of the project, data for about 200
patients with a suspected monogenic disease have
been collected. Two diagnostic steps provide ﬁrst for the
selection of suspected phenotypes and then for the
identiﬁcation of patients with a positive genetic test for
each speciﬁc disease. Of the patients included so far,
39% were screened for CADASIL, 13% for Fabry dis-
ease, 27% for H-CAA, 6% for MELAS, 11% for
FHM/SHM and 3% for Marfan syndrome. The ﬁnal ex-
pectation is that physicians will be able to apply, in their
everyday clinical practice, the diagnostic tools for mono-
genic disease acquired through their participation in this
project.
Discussion
The Lombardia GENS project will provide a database of
well-phenotyped stroke patients with diagnoses of
monogenic disorders. Despite the fact that stroke-asso-
ciated monogenic diseases are rare and most strokes
are believed to be polygenic, diagnosis of single-gene
disorders is needed because some have proven
amenable to disease-speciﬁc treatments. Moreover, a
correct diagnosis may provide a concrete beneﬁt to af-
fected individuals in terms of prognostic evaluation, ge-
netic counseling, and speciﬁc management measures
(3,4). 
Most of the available studies on single-gene disorders
are underpowered because they included only a small
number of cases and were conducted at individual cen-
ters. Moreover, given ongoing results in terms of the ge-
netic factors underlying polygenic stroke pathogenesis,
careful phenotype characterization and accurate geno-
type-phenotype correlations, in addition to further insight
into the pathogenesis of monogenic disorders, may help
to clarify some pathogenic bases of heritable stroke
(3,7-9). 
Unlike previous studies in this field, which focused on
only one monogenic disease (10-18), Lombardia
GENS is, to our knowledge, the largest genetic net-
work, allowing the recruitment of a high number of pa-
tients suspected of having monogenic disorders, in
which the cerebrovascular event is the mandatory in-
clusion criterion. It has a high probability of success
as it favors the collaboration of people (physicians,
geneticists, biologists) involved in stroke genetics re-
search. The participation of clinicians in the project fa-
cilitates collection of well-characterized populations
and the translation of research outcomes into clinical
practice, with the aim of identifying possible etiological
factors involved in stroke pathogenesis and new treat-
ment modalities for all stroke subtypes. Through Lom-
bardia GENS, stroke genetics laboratories are offered
an opportunity to standardize procedures and to in-
crease their research potential, avoiding the risk of di-
luting effort and delaying outcome. Moreover, the proj-
ect will help to promote adequate education and train-
ing across the health professions, raising awareness
of the existence of these diseases and of the re-
sources available for their diagnosis and treatment. 
The project will also give stroke patients with rare dis-
eases increased access to care, resources, and expert-
ise, reducing misdiagnosis and non-diagnosis of mono-
genic diseases and improving their quality of life. In ad-
dition, it will lead to the identiﬁcation of centers of expert-
ise throughout the country and organized healthcare
pathways for patients suffering from monogenic dis-
eases. The large patient dataset planned for this project
may help to make the diagnosis of monogenic diseases
more straightforward, increasing the accuracy of epi-
demiologic data on the incidence of rare diseases in
stroke and knowledge of disease phenotypes, and har-
nessing the power needed to make signiﬁcant geno-
type-phenotype correlations. 
The project does, however, present some methodologi-
cal limits. First, although the participating clinical centers
hospitalize most stroke patients in Lombardy, the cases
are recruited through selected hospitals which do not
provide full coverage of the geographical area. More-
over, hospital-based sampling frames do not allow a true
measure of population incidence. Second, the cases are
recruited through stroke centers and the presence of
stroke or TIA is an inclusion criterion; the data are bi-
ased by these criteria which allow the inclusion only of
symptomatic patients. The objective of recruiting about
300 cases overall across all subgroups will also limit
multiple risk factor analysis studies. 
Nevertheless, the project could continue in future years
and yield a network model that could be extended to
other regions and countries. Because rare diseases
continue to be a priority of the European Community,
mostly with regard to developing new diagnostics and
treatments, as well as performing epidemiological re-
search into these disorders, multicountry or multicenter
comprehensive approaches to increase the number of
patients included for study are considered to be highly
valuable.
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2. Stroke event
◆ Date and time of event   ___/___/____              ____ : ____
◆ Type: 
• TIA ❑ • Stroke ❑
◆ Subtype 
• Ischemic ❑ • Hemorrhagic ❑
◆ First event: 
• Yes ❑ No ❑
If no, type and number of previous events: 
❑ TIA       n. ___ ❑ Stroke    n. ___
◆ NIHSS (ﬁrst available) _____   Date and time     ___/___/____   _____:____
• Direct examination ❑ • Derived from clinical notes ❑
◆ Pre-stroke Rankin score ______
• Direct examination ❑ • Derived from clinical notes ❑
Appendix 1 - Characteristics of patients with suspected monogenic disease
LOMBARDIA GENS
1. Demographics
◆ Hospital name  …………………………………………………………………………………………………………………………………
◆ First name and Surname  …………………………………………………………………………………………………
◆ Date of birth    ___/___/____         ◆ Place of birth
…………………………………………………………………………………………
◆ Sex • Male ❑ • Female ❑
◆ Region of origin …………………………………………………………………………………………………..
◆ Phone…………………………………………………………………………………………………………………………… 
◆ Ethnic group: 
• Caucasian ❑ •  Asian ❑
• Hispanic ❑ •  Black ❑
◆ Date of examination       ___/___/____
◆ Date of blood extraction    ___/___/____
◆ Type of examination:      
• Emergency dept ❑
• inpatient ❑
• outpatient ❑
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3. Neurological examination
• Direct examination       ❑ • Derived from clinical notes    ❑
• Strength deﬁcit (paresis/plegia)                 Left   ❑ Right   ❑ Both ❑
• Sensory deﬁcit                             Left   ❑ Right   ❑ Both ❑
• Aphasia  Yes   ❑ No     ❑
• Visual defects Yes   ❑ No     ❑
• Heminattention Yes   ❑ No     ❑
• Consciousness impairment Yes   ❑ No     ❑
• Dysarthria  Yes   ❑ No     ❑
• Ataxia  Yes   ❑ No     ❑
• Other   ………………………………………………………………………………………………………………………………………….
4. Diagnosis (Please attach copy of report)
◆ Neuroimaging:         
• CT ❑ • MRI ❑
◆ Cerebral vascular imaging:
• Doppler US ❑ • MRA/CTA/cerebral angiography ❑
5. Risk factors
◆ High blood pressure (≥160/95 mmHg  and/or previous history of high BP):
• Yes   ❑ • No  ❑
◆ Diabetes (glycemia ≥126 mg/dl and/or previous history of diabetes):
• Yes  ❑ • No  ❑
◆ Dyslipidemia (cholesterol≥200 mg/dl and/or tryglicerides≥180 mg/dl and/or previous history of dyslipidemia):
• Yes  ❑ No ❑
◆ Ischemic cardiopathy (previous MI and/or angina  and/or endovascular treatment of coronary arteries):
• Yes  ❑ No ❑
◆ AF (on the basis of the ECG and/or previous detection):
• Yes  ❑ No ❑
◆ Peripheral vasculopathy (stenosis/occlusion of peripheral vessel and/or previous history of intermittent claudication):
• Yes  ❑ No ❑
◆ Smoking:
• never          ❑
• in the past   ❑ date of stopping:  ___/___/____
• current        ❑ number of cigarettes /day  _______
◆ Weight (kg)______ ◆ Height (cm)  ______
◆ Physical inactivity (<60 min/d):
• Yes  ❑ No ❑
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7. Family History
◆ Consanguineous parents Yes ❑ No ❑
◆ Father:
• Date of birth     ___/___/____ • Place of birth    ______________________    (____)
• Diseases:
Stroke ❑ Psychiatric disturbances ❑
◆ Hormone therapy (HRT or contraceptive):
• Yes  ❑ No ❑
◆ Alcool abuse (>32 g for and ≥16 g for ):
• Yes  ❑ No ❑
◆ Hyperhomocysteinemia (homocysteine >15 units):
• Yes  ❑ No ❑
◆ Other
………………………………………………………………………………………………………………………………………………………
6. Associated Symptoms and Signs (previous or current)
◆ Migraine/headache Yes ❑ No ❑
◆ Seizures Yes ❑ No ❑
◆ Psychiatric disturbances Yes ❑ No ❑
If yes specify………………………………………………………………………………………………………………………………….. 
◆ Cognitive impairment Yes ❑ No ❑
◆ Deafness Yes ❑ No ❑
◆ Short/tall stature Yes ❑ No ❑
◆ Renal failure Yes ❑ No ❑
◆ Spontaneous abortion Yes ❑ No ❑
◆ Cardiopathy Yes ❑ No ❑
◆ Skin lesions (neuroﬁbromas, angiokeratomas) Yes ❑ No ❑
◆ Dysmorphisms Yes ❑ No ❑
◆ Joint ﬂexibility Yes ❑ No ❑
◆ Acroparesthesias Yes ❑ No ❑
◆ Myopathy with or without exhaustibility Yes ❑ No ❑
◆ Lactic acidosis Yes ❑ No ❑
◆ Sickle cell disease Yes ❑ No ❑
Migraine ❑ Coagulopathies ❑
Renal failure  ❑ Epilepsy ❑
Dementia ❑ Myopathies ❑
• Alive Yes ❑ No ❑
If no:  Age at death     _______
Cause of death  ………………………………………………………………………………………………………
………………………………………………………………………………………………………………….........…
◆ Mother:
• Date of birth     ___/___/____ • Place of birth    ______________________    (____)
• Diseases:
Stroke ❑ Psychiatric disturbances ❑
Migraine ❑ Coagulopathies ❑
Renal failure ❑ Epilepsy ❑
Dementia ❑ Myopathies ❑
• Alive Yes ❑ No ❑
If no:  Age at death     _______
Cause of death  ………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………….
◆ Brothers/sisters:  
• Date of birth     ___/___/____ • Place of birth    ______________________    (____)
• Diseases:
Stroke ❑ Psychiatric disturbances ❑
Migraine ❑ Coagulopathies ❑
Renal failure ❑ Epilepsy ❑
Dementia ❑ Myopathies ❑
• Alive Yes ❑ No ❑
If no:  Age at death     _______
Cause of death  ………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………….
◆ Sons/daughters: 
• Date of birth     ___/___/____ • Place of birth    ______________________    (____)
• Diseases:
Stroke ❑ Psychiatric disturbances ❑
Migraine ❑ Coagulopathies ❑
Renal failure ❑ Epilepsy ❑
Dementia ❑ Myopathies ❑
• Alive Yes ❑ No ❑
If no:  Age at death     _______
Cause of death  ………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………….
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Appendix 2 - Characteristics of patients with suspected monogenic disease
LOMBARDIA GENS
CADASIL
Diagnosis
1)  Subcortical lacunar T2 sequence lesions at MRI.                                                                      
2) At least one of the following signs/symptoms
❑ History of recurrent stroke /TIA 
❑ Migraine with aura
❑ Dementia
❑ Major mood disorders
❑ Family history of stroke/mood disorders and/or migraine and/or dementia  
__________________________________________________________________________________________
Laboratory  diagnosis
1) Genetic analysis 
➢ Genetics Laboratory, Niguarda Ca’ Granda  Hospital (Dr Penco)
Screening exons: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
➢ Biochemistry and Genetics Laboratory, Carlo Besta Institute of Neurology Foundation, IRCCS (Dr Taroni / Dr
Gellera) 
Screening exons: 3, 4, 11; if high suspicion 2, 5, 6, 8, 19; 7, 9, 10, 14, 18, 20, 22, 23; 1, 12, 13, 15,
16,17,21
➢ Molecular Biology Laboratory, San Raffaele del Monte Tabor Foundation, IRCCS, Università Vita-Salute, San
Raffaele Hospital, IRCCS (Dr Carrera / Dr Calzavara)
Screening exons: 2, 3, 4, 5, 6, 8, 11, 12, 14, 18, 19, 20, 22, 23
2) Skin biopsy 
➢ Neuropathology Unit, Carlo Besta Institute of Neurology Foundation, IRCCS (Dr Tagliavini / Dr Morbin)
➢ Pediatric Dermatology Laboratory, Ca’ Granda Foundation, Maggiore Policlinico Hospital, IRCCS, University
of Milan (Dr Tadini)
MELAS
Diagnosis
1) Stroke-like episodes (mostly cortical and not related to a vascular territory) in patients younger than 45 years 
2) At least one of the following signs/symptoms: 
❑ Myopathy with lactic acidosis
❑ Seizures
❑ Migraine
❑ Typical lesions on MRI (bitemporal and basal ganglia calciﬁcation) 
❑ Cardiomyopathy
❑ Progressive dementia
❑ Metal retardation
❑ Short stature 
❑ Diabetes
❑ Deafness
___________________________________________________________________________________________
Laboratory diagnosis
Search for A3243G mutation in tRNALeu gene:
➢ Biochemistry and Genetics Laboratory, Department of Neurological Sciences, Ca’ Granda Foundation, Mag-
giore Policlinico Hospital, IRCCS, University of Milan (Prof. Comi) 
If cardiomyopathy: 
Whole  MtDNA sequencing:
➢ Center of Genetic Cardiovascular Diseases (Director: Prof. Arbustini) - Molecular Genetics Laboratory (Dr
Grasso / Dr Marziliano / Dr Diegoli) San Matteo Hospital Foundation, IRCCS, Pavia
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FAMILIAL OR SPORADIC HEMIPLEGIC MIGRAINE (FHM/SHM)
Diagnosis
1) At least two migraine aura attacks associated with motor weakness (hemiparesis, paresis, plegia) lasting >5 min and <24 h
2) At least one of the following signs/symptoms:
❑ Fully reversible visual symptoms including positive features (e.g., ﬂickering lights, spots or lines) and/or negative features (i.e.,
loss of vision)
❑ Fully reversible sensory symptoms including positive features (i.e., pins and needles) and/or negative features (i.e., numbness)
❑ Fully reversible dysphasic speech disturbance
❑ Supplementary clinical features: 
• Migraine following aura.
• Childhood onset migraine  (<30 years) 
• At least one ﬁrst- or second-degree relative has had attacks fulﬁlling these criteria 
• Progressive ataxia and/or nystagmus
• Attacks triggered by fever, trauma, pleocytosis
___________________________________________________________________________
Laboratory diagnosis 
Screening CACNA1A gene (FHM1)  (exons 3, 4, 5, 6, 11, 13, 14, 16, 17, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34,
35, 36, 41, 42, 47), ATP 1A2 gene (FHM2) (all exons) and  SCN1A gene (FHM3) (exons 23, 26):
Genetics Laboratory, Eugenio Medea Institute, Bosisio Parini, Lecco (Dr Bassi) 
➢ Molecular Biology Laboratory, San  Raffaele del Monte Tabor Foundation, IRCCS, Università Vita-Salute, San
Raffaele Hospital, IRCCS (Dr Carrera), Milan
CEREBRAL HERITABLE AMYLOID ANGIOPATHY (H-CAA)
Diagnosis
1) At least one of the following signs:
❑ Recurrent atypical hemorrhage (mostly cortical and subcortical)
❑ Ischemic/hemorrhagic lesions not attributable to a different disorder
❑ Cerebral MRI consistent with the suspicion of amyloid angiopathy
2) At least one of the following signs/symptoms:
❑ Lack of hypertension or well treated hypertension)
❑ Lack of coagulation abnormalities 
❑ Absence of aneurysms or arteriovenous malformations
❑ Positive family history of hemorrhagic and ischemic stroke
❑ Cognitive impairment
❑ Occipital calciﬁcations
❑ Sensory-motor peripheral neuropathies
________________________________________________________________________________________
Laboratory  diagnosis
Genetic screening of TTR, APP, CYSTATIN C genes: 
➢ Biotechnology and Biomedical Technology Laboratory, Systemic Amyloidosis Study Center, San Matteo Ho-
spital Foundation, IRCCS, Pavia (Dr Obici / Prof. Merlini), Pavia 
MARFAN SYNDROME
Clinical diagnosis
1) Ischemic or hemorrhagic stroke due to arterial dissection, rupture of intracranial aneurysms or cardioembolic source 
2) At least two of the following criteria: 
❑ At least two skeletal abnormalities (tall stature, pectus excavatum or carinatum, high-arched palate, arachnodactyly, laxity of lig-
aments with scoliosis, or joint hyperextensibility) 
❑ At least two ocular manifestations (strabismus, amblyopia, ectopia lentis, cataract) 
❑ At least one cardiovascular manifestation (dissection or dilatation of ascending aorta, mitral valve prolapse, cardiac arrhyth-
mias)
❑ At least one cutaneous manifestation (cutaneous striae, recurrent hernias) 
❑ At least one pulmonary manifestation (spontaneous pneumothorax, apical bubbles)
❑ Positive familial history of arterial dissections, skeletal abnormalities, typical cardiovascular and ocular manifestations) 
________________________________________________________________________________________
Laboratory diagnosis
Screening of FBN1 and TGFβ-R2 genes: 
➢ Center of Genetic Cardiovascular Diseases (Director: Prof. Arbustini) - Molecular Genetics Laboratory
(Dr Grasso / Dr Marziliano / Dr Diegoli) San Matteo Hospital Foundation, IRCCS, Pavia

